Where does OstomyCure AS rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), OstomyCure AS ranks #14,836 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does OstomyCure AS hold?

OstomyCure AS holds 20 US utility patents granted between 2015 and 2025, spanning 2 technology areas.

What is OstomyCure AS's Innovation Score?

OstomyCure AS has an Innovation Score of 36.4 out of 100 (top 46% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is OstomyCure AS's patent grant rate increasing or decreasing?

OstomyCure AS's recent grant velocity is -69% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for OstomyCure AS's patents?

OstomyCure AS's patents average 12.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the OstomyCure AS patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

OstomyCure AS

Q: What technology areas does OstomyCure AS focus on?

OstomyCure AS's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 12 patents, ranking #539 of 3,082 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

USPTO PatentsView assignee record - 20 granted patents across 2 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ostomycure ranks #14,836 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 2 technology areas.

#14,836
of 49,997 US assignees by volume: Top 46%
by Innovation Score (36.4/100): 12.7
avg claims per patent: -69%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14836 · Foreign Corporation #14,836 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 20 grants
MID-PACK #14,836/49,997
PHOTO-FINISH Olin
CPC-NARROW A61F · 2 areas
INNOV-THIN 36.4/100
CLAIMS-RICH 12.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -69% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Olin Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ostomycure’s 36.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (29%) Velocity 13.3 pts (37%) Breadth 5.0 pts (14%) Claim depth 7.6 pts (21%)

Qualcomm Incorporated · highest

85
OstomyCure AS · this assignee

36
3D Lighting… · lowest

7

What this shows Ostomycure's Innovation Score is 36.4/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ostomycure?

Each dot is one of Ostomycure’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ostomycure’s own 12.7 claims/patent is at or below the 13.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Ostomycure vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ostomycure's grants concentrate

OstomyCure AS is a focused PatentsView assignee: 2 CPC subclasses with 60% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2018 (5 grants) versus a trough of 1 in 2022. By volume, Ostomycure sits between Olin Corporation and Paion UK Limited.

Ostomycure's three-year grant acceleration

OstomyCure AS shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Olin

20
Omega (Omega )(Om…

20
Oneida Air Systems

20
Optovate

20
Otonexus Medical

20
Otsuka Medical De…

20
Owl biomedical

20
Paion UK

20
Ostomycure AS ◀

20

What this shows OstomyCure holds 20 patents at rank #14,833, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near OstomyCure

By rank, the assignees closest to #14,833 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in OstomyCure's primary technology class.

Ostomycure's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 46% higher than 54% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

OstomyCure AS patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	10.0%
2016	2	10.0%
2017	2	10.0%
2018	5	25.0%
2019	2	10.0%
2022	1	5.0%
2023	2	10.0%
2024	1	5.0%
2025partial year	3	15.0%

Which technologies does OstomyCure AS patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 12

Y10T - Technical Subjects Covered BY Former US Classification 1

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

OstomyCure AS's patent record in context - here's where to go next.

OstomyCure AS's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 60% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #14,836 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare OstomyCure AS against Olin Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.